Merck & Co., Inc. (MRK)

NYSE: MRK · IEX Real-Time Price · USD
-2.07 (-1.87%)
At close: Dec 9, 2022 4:03 PM
-0.02 (-0.02%)
After-hours: Dec 9, 2022 4:36 PM EST
Market Cap 281.05B
Revenue (ttm) 58.97B
Net Income (ttm) 15.26B
Shares Out 2.53B
EPS (ttm) 6.03
PE Ratio 18.04
Forward PE 14.56
Dividend $2.76 (2.54%)
Ex-Dividend Date Dec 14, 2022
Volume 9,090,362
Open 110.98
Previous Close 110.85
Day's Range 108.75 - 111.37
52-Week Range 71.97 - 111.37
Beta 0.41
Analysts Buy
Price Target 112.55 (+3.5%)
Earnings Date Oct 27, 2022

About MRK

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions an... [Read more]

Industry Pharmaceuticals
Founded 2000
CEO Kenneth Frazier
Employees 67,000
Stock Exchange NYSE
Ticker Symbol MRK
Full Company Profile

Financial Performance

In 2021, Merck & Co.'s revenue was $48.70 billion, an increase of 17.31% compared to the previous year's $41.52 billion. Earnings were $13.05 billion, an increase of 84.65%.

Financial Statements

Analyst Forecast

According to 32 analysts, the average rating for MRK stock is "Buy." The 12-month stock price forecast is 112.55, which is an increase of 3.47% from the latest price.

Price Target
(3.47% upside)
Analyst Consensus: Buy
Stock Forecasts


Merck (MRK) Is Up 2.36% in One Week: What You Should Know

Does Merck (MRK) have what it takes to be a top stock pick for momentum investors? Let's find out.

3 hours ago - Zacks Investment Research

Final Trades: Stryker, Southwest Gas, Freeport-McMoRan & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: FCXSWXSYK
1 day ago - CNBC Television

4 Defensive Stocks to Prepare Your Portfolio for a Recession

Amid the rising possibility of a recession, defensive stocks with solid prospects will cushion investors from market jitters while their robust fundamentals ensure higher returns. ADM, HSY, UNH and MRK ...

Other symbols: ADMHSYUNH
2 days ago - Zacks Investment Research

3 High-Yielding Stocks That Are Up 27%-Plus This Year

Is it too late to buy these soaring stocks?

Other symbols: CVXGIS
2 days ago - The Motley Fool

Is Merck Stock A Buy After Surging To A Fresh High On Its Imago Buyout Plans?

Is Merck stock a buy after the company announced its acquisition of Imago, a bone marrow diseases company? Is MRK stock a buy now?

3 days ago - Investors Business Daily

Should Investors Consider These 3 Low-Beta Stocks?

During times of heightened volatility, adding low-beta stocks can help blend in an extra layer of portfolio defense.

Other symbols: GISSJM
6 days ago - Zacks Investment Research

Top 4 Blue-Chip Stocks to Enhance Your Portfolio in December

We have narrowed our search to four Dow stocks. These are: CAT, WMT, MRK, UNH.

Other symbols: CATUNHWMT
1 week ago - Zacks Investment Research

Hot Fund To SEC: We're Boosting Bets On Best Stock Picks

Wondering how to invest in stocks and mutual funds amid a grim market? Red-hot Invesco Comstock Select Fund is doubling down on its strategy.

Other symbols: WFCXOM
1 week ago - Investors Business Daily

3 Reasons Growth Investors Will Love Merck (MRK)

Merck (MRK) could produce exceptional returns because of its solid growth attributes.

1 week ago - Zacks Investment Research

3 Stocks to Watch That Recently Announced Dividend Hikes

Merck & Co., Inc. (MRK), McCormick & Company, Incorporated (MKC) and Tsakos Energy Navigation Limited (TNP) recently hiked dividends.

Other symbols: MKCTNP
1 week ago - Zacks Investment Research

Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology...

RAHWAY, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from clinical trials and real-world studies at the ...

1 week ago - Business Wire

Gurus Prescribed These Health Care Stocks in the 3rd Quarter

Amid rising concerns about the state of the global economy, rising inflation, central bank interest rate hikes and increased Covid-19 restrictions in China, marked indexes were mixed on Wednesday morning.

1 week ago - GuruFocus

Three-Stock Lunch: PayPal, Merck and Broadcom

Quint Tatro, Joule Financial founder and CEO, joins 'Power Lunch' to discuss his investing take on three stocks: PayPal, Merck and Broadcom.

Other symbols: AVGOPYPL
1 week ago - CNBC Television

Merck Announces First-Quarter 2023 Dividend

RAHWAY, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.73 per share...

1 week ago - Business Wire

At All-Time Highs, Merck's Stock Is Nearing a Cliff

Throughout the beginning of the Covid-19 pandemic, pharmaceutical companies were mostly focused on the availability and effectiveness of vaccines. However, around December 2021, the focus shifted more t...

1 week ago - GuruFocus

Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?

Recently, users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

1 week ago - Zacks Investment Research

3 Dow Stocks to Take Seriously in 2023

The Dow Jones Industrial Average is down more than 6% year-to-date. With slightly more than half of the index in negative territory for the year, it is easier to come up with three of the top Dow stocks...

Other symbols: AAPLHD
1 week ago - InvestorPlace

Merck & Co., Inc. (MRK) Hits Fresh High: Is There Still Room to Run?

Merck (MRK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

1 week ago - Zacks Investment Research

3 Biotech Stocks Smart Investors Should Be Buying Up Now

For investors looking for growth, biotech stocks are a great place to start one's search. This is a sector that's seen its valuation multiples decline in many cases to a greater extent than the overall ...

Other symbols: ARDXNVS
2 weeks ago - InvestorPlace

Merck (MRK) Keytruda Advanced Gastric Cancer Study Meets Goal

Top-line data from a late-stage study shows that Merck's (MRK) Keytruda combined with chemotherapy improved overall survival in patients with advanced gastric cancer.

2 weeks ago - Zacks Investment Research

IMAGO BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Ade...

NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Imago BioScience...

Other symbols: IMGO
2 weeks ago - Business Wire

3 Undervalued Dow Stocks to Buy Before Wall Street Catches On

The Dow Jones Industrial Average is down around 6.2% year to date. Of the 30 stocks in the index, 14 are down at least 10% for the year.

Other symbols: CVXHD
2 weeks ago - InvestorPlace

Buy These 5 Corporate Giants Flying High in Disappointing 2022

We have narrowed our search to five U.S. corporate behemoths that have popped year to date. These are: ADM, MPC, XOM, MRK and MCK.

Other symbols: ADMMCKMPCXOM
2 weeks ago - Zacks Investment Research

Japan approves COVID antiviral pill as Pfizer, Merck alternative

TOKYO—Japan approved an antiviral pill from Shionogi & Co. to treat Covid-19 after the company provided new data to show the drug's efficacy.

Other symbols: PFE
2 weeks ago - Market Watch

Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gas...

RAHWAY, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 KEYNOTE-859 trial investigatin...

2 weeks ago - Business Wire